Macrogenics Inc SEC Filings

MacroGenics, Inc. senior vice president Thomas Spitznagel reported routine equity award activity. On February 7 and 8, 2026, restricted stock units converted into 6,001 and 8,999 shares of common stock, respectively, on a one-for-one basis. On each date, 2,485 and 3,186 shares were withheld at $1.81 per share to cover taxes. After these transactions, Spitznagel directly owned 30,731 shares of MacroGenics common stock.

MacroGenics VP, Controller & Treasurer Beth Ann Smith reported routine equity compensation activity involving restricted stock units (RSUs) and common stock. On February 7, 2026, 2,617 RSUs converted into 2,617 shares of common stock at an exercise price of $0, with 1,011 shares of common stock withheld at $1.81 per share, leaving 11,138 shares directly owned afterward. On February 8, 2026, a further 1,583 RSUs converted into 1,583 shares of common stock at $0, with 612 shares withheld at $1.81 per share, resulting in 12,109 common shares directly owned. RSUs convert into company stock on a one-for-one basis, and remaining RSU balances after these transactions were 5,233 and 1,584 units for the two respective grants.

MacroGenics (MGNX) President and CEO Eric Blasius Risser reported multiple equity award transactions in early February 2026. On February 7, 2026, 6,668 restricted stock units (RSUs) converted on a one-for-one basis into common stock, increasing his direct holdings to 62,657 shares before a 2,575-share disposition at $1.81 per share, leaving 60,082 shares.

On February 8, 2026, a further 11,166 RSUs converted into common stock, taking his direct common stock position to 71,248 shares before a 4,311-share disposition at $1.81 per share, resulting in 66,937 common shares directly owned. Following these transactions, he held 13,332 RSUs from a February 7, 2025 grant of 20,000 units and 11,166 RSUs from a February 8, 2024 grant of 33,500 units, each vesting in three equal annual installments.

MacroGenics, Inc. insider activity: Senior VP, General Counsel and Secretary Jeffrey Stuart Peters reported routine equity compensation events. On February 7 and 8, 2026, portions of previously granted restricted stock units vested and were converted into common stock on a one-for-one basis.

On those dates, a total of 6,001 and 8,999 common shares, respectively, were acquired upon RSU conversion at an exercise price of $0. In connection with these vestings, 2,317 and 3,474 shares of common stock were withheld at $1.81 per share to satisfy tax obligations, coded as transaction type “F.”

Following the reported transactions, Peters directly held 22,920 shares of MacroGenics common stock. He also continued to hold derivative positions in restricted stock units from earlier grants, which were originally 18,000 units granted on February 7, 2025 and 27,000 units granted on February 8, 2024, each vesting in three equal annual installments.

MacroGenics SVP and CFO James Karrels reported routine equity award activity. On February 7 and 8, 2026, restricted stock units converted into 6,334 and 9,999 shares of common stock, respectively, on a one-for-one basis. In connection with these vestings, 2,446 and 3,860 shares of common stock were withheld at $1.81 per share to cover tax obligations.

After these transactions, Karrels beneficially owned 196,828 shares of MacroGenics common stock, held directly and jointly with his wife, plus 12,666 and 9,999 remaining restricted stock units from prior grants that continue to vest over time.

MacroGenics Inc. insider activity: Sr VP, Research & CSO Ezio Bonvini reported routine equity transactions on February 7 and 8, 2026 involving restricted stock units (RSUs) and common stock of MacroGenics Inc. (MGNX).

On February 7, RSUs converting on a one-for-one basis were exercised for 7,001 shares of common stock, increasing his directly held common stock to 131,415 shares, while 2,703 shares were withheld at a price of $1.81 per share, leaving 128,712 shares directly owned. On February 8, an additional 11,166 RSUs were exercised into common stock, bringing direct common stock holdings to 139,878 shares before 4,311 shares were withheld at $1.81 per share, resulting in 135,567 directly owned common shares.

Following these transactions, Bonvini also held 13,999 RSUs from a February 7, 2025 grant of 21,000 RSUs vesting in three equal installments and 11,166 RSUs from a February 8, 2024 grant of 33,500 RSUs, also vesting in three equal installments beginning on the first anniversary of each grant date.

MacroGenics, Inc. announced that Stephen Eck, M.D., Ph.D., its Senior Vice President, Clinical Development and Chief Medical Officer, will depart the company effective December 31, 2025, following a mutual agreement reached on November 14, 2025. Oversight of clinical development will be handled on an interim basis by Frank Perabo, M.D., Ph.D., Vice President, Clinical Development, while an executive recruiter conducts a search for a new Chief Medical Officer. Dr. Eck, who joined MacroGenics in July 2020 and led clinical development across multiple studies, will receive payments and benefits for a qualifying termination in accordance with his employment agreement, conditioned on a general release, waiver of claims, and compliance with his restrictive covenants.

MacroGenics (MGNX)Exhibit 99.1 to this Form 8-K. The information in this report, including Exhibit 99.1, is provided as “furnished” under the Exchange Act and is not deemed “filed.”

MacroGenics, Inc. reported Q3 results showing total revenue of $72.8 million versus $110.7 million a year ago, reflecting lower milestone revenue, partly offset by stronger contract manufacturing. Contract manufacturing revenue rose to $19.8 million from $4.6 million. Research and development expense declined to $32.7 million from $40.5 million.

The company generated quarterly net income of $16.8 million (basic and diluted EPS $0.27), compared with $56.3 million last year. Year to date, it recorded a net loss of $60.5 million as operating cash outflows reached $124.1 million. Cash and cash equivalents were $80.1 million with marketable securities of $66.3 million. Stockholders’ equity was $67.0 million.

In June, MacroGenics sold future ZYNYZ royalties to Sagard for $70.0 million, recognizing a liability of $70.3 million with an estimated effective interest rate of 18.6% and booked $3.3 million non-cash interest in Q3. It also recognized $50.0 million from two Sanofi regulatory milestones, included in accounts receivable at quarter end. Subsequent to quarter end, Gilead nominated a second research program and exercised its option, obligating a total of $25.0 million. Shares outstanding were 63,258,532 as of November 7, 2025. Management cites a cash runway into late 2027.